TY -的T1 -循环纤维细胞作为一种新的工具来预测肺癌手术后进展吗?摩根富林明-欧洲呼吸杂志》乔和J - 10.1183/13993003.01221 -2021欧元SP - 2101221 AU -波林Henrot盟-法比Beaufils AU -马修Thumerel盟Edmee Eyraud AU - Augustin Boudoussier盟Hugues Begueret AU -爱丽丝Maurat盟Pierre-Olivier Girodet AU -罗杰Marthan AU -帕特里克·伯杰盟伊莎贝尔杜宾AU - Zysman Maeva Y1 - 2021/01/01 UR - //www.qdcxjkg.com/content/early/2021/09/09/13993003.01221 - 2021. -抽象N2 -肺癌是癌症死亡的主要原因。2008年,报告了2206771例新病例和1796144例死亡[1]。在诊断,大约三分之一的病人有潜在可切除的肿瘤局限于胸部没有临床证据的纵隔淋巴结病(临床阶段I和II)。然而,即使在完整的手术切除,这种早期疾病患者的总体生存仍然令人失望。患者的5年生存率甚至IA期或IB非小细胞肺癌(NSCLC)是73%和56%,分别[2]。此外,手术后5年当地或区域复发的风险仅为非小细胞肺癌阶段IA、IB、活动花絮,IIB, iii a也很高(16%、23%、37%、39%和30%,分别[3])。5年生存的小细胞肺癌(SCLC)患者早期切除病(T1, 2 N0M0)大致相似,大约50% [4]。复发的疾病在遥远的地点,尽管完全删除所有的宏观损伤,是治疗失败的主要原因[5 - 8]。的存在micro-metastatic疾病切除这种复发的可能的原因。然而,微传播的机制还有待阐明。FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Henrot has nothing to disclose.Dr. Henrot reports non-financial support from Avad, outside the submitted work.Conflict of interest: Dr. Beaufils reports personal fees and non-financial support from Novartis, personal fees and non-financial support from Chiesi, personal fees and non-financial support from AstraZeneca, outside the submitted work.Conflict of interest: Dr. Thumerel has nothing to disclose.Conflict of interest: Dr. Eyraud has nothing to disclose.Conflict of interest: Dr. Boudoussier has nothing to disclose.Conflict of interest: Dr. BEGUERET has nothing to disclose.Conflict of interest: Dr. Maurat has nothing to disclose.Conflict of interest: Dr. Girodet reports grants, personal fees and non-financial support from AstraZeneca, personal fees and non-financial support from Chiesi, personal fees and non-financial support from GlaxoSmithKline, personal fees and non-financial support from Novartis, personal fees and non-financial support from Sanofi, outside the submitted work.Conflict of interest: Dr. Marthan has nothing to disclose.Conflict of interest: Dr. Berger reports grants, personal fees and non-financial support from AstraZeneca, personal fees and non-financial support from Chiesi, personal fees and non-financial support from GlaxoSmithKline, personal fees and non-financial support from Novartis, personal fees and non-financial support from Sanofi, outside the submitted work.Conflict of interest: Dr. Dupin reports grants from Fondation Bordeaux Université, during the conduct of the study; In addition, Dr. Dupin has a patent (EP N°15152886.6 i.e. New compositions and methods of treating and/or preventing Chronic Obstructive Pulmonary Disease) pending.Conflict of interest: Dr. Zysman reports grants and personal fees from Astra Zeneca, personal fees from GSK, personal fees from Boehringer Ingelheim, personal fees from CSL Behring, personal fees from Chiesi, outside the submitted work. ER -